Ipsen Shares Fall 7% After US Approval of Generic Somatuline Rival

3-line summary

• Ipsen shares fell 7% after the US approved a generic rival to its Somatuline drug, according to Investing.com.

This summary is our own processing of the source article; see the source link below for full context.